Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton(Penn State Milton S. Hershey Medical Center), Karim Fizazi(Université Paris-Sud), Alison Stopeck(University of Arizona), David H. Henry(Pennsylvania Hospital), Janet E. Brown(Cancer Research UK), Denise A. Yardley(Tennessee Oncology), Gary Richardson(Cabrini Hospital), Salvatore Siena(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Pablo Maroto(Hospital de Sant Pau), Michael Clemens(Klinikum Mutterhaus der Borromäerinnen), Boris Bilynskyy, Veena Charu, Philippe Beuzeboc(Institut Curie), Michael Rader(Nyack Hospital), María Eugenia Ibarrarán Viniegra(National University of General San Martín), Fred Saad(Université de Montréal), Chunlei Ke(Amgen (United States)), Ada Braun(Amgen (United States)), Susie Jun(Amgen (United States))
Cited by 587
Abstract
Related Papers
No related papers found
Powered by citation graph analysis